Cue Biopharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 50.73 million compared to USD 53.01 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.49 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9402 USD | -0.85% | -2.06% | -64.39% |
Jul. 01 | Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000E Growth Index | CI |
Jul. 01 | Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.39% | 45.73M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CUE Stock
- News Cue Biopharma, Inc.
- Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023